Andrea Lobo,  —

Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto, in drug addiction, studying neuronal plasticity induced by amphetamines. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, from stroke, gene regulation, cancer, and rare diseases. She authored multiple research papers in peer-reviewed journals. She shifted towards a career in science writing and communication in 2022.

Articles by Andrea Lobo

Switch to Takhzyro found to reduce cardiovascular risk for HAE patient

Switching from long-term androgen treatment to Takhzyro (lanadelumab) successfully prevented swelling attacks and reduced cardiovascular risk in a man with hereditary angioedema (HAE) type 1, according to a report from Italy. The man had undergone two kidney transplants and was on immunosuppressant medications for several years. According to…

Lack of first-line options in India impacts pediatric HAE treatment

Preventing swelling attacks in children in India with hereditary angioedema (HAE) relies mostly on using tranexamic acid (TA) and attenuated androgens, or male hormones, due to the lack of accessible first-line treatment options, a single-center study shows. Neither therapy is preferred for HAE and attenuated androgens are contraindicated…

Kalvista asks 4 countries to OK sebetralstat as treatment for HAE

Kalvista Pharmaceuticals has submitted applications to regulatory authorities in the U.K., Switzerland, Australia, and Singapore requesting the approval of sebetralstat, an oral, on-demand treatment for hereditary angioedema (HAE) in patients ages 12 and older. The four applications were submitted through the Access Consortium framework, a coalition of…

ACE inhibitor deemed cause of man’s angioedema: Case report

A man who experienced recurrent episodes of tongue swelling was diagnosed with angioedema related to the use of an angiotensin-converting enzyme (ACE) inhibitor to treat high blood pressure, according to a case report. The patient’s symptoms eased after stopping treatment with the medication, lisinopril, with no recurrence of angioedema…

Phase 3 trial to test extended deucrictibant as treatment for HAE

Pharvaris said it plans to initiate a Phase 3 clinical trial by the end of the year to test an oral, extended-release tablet formulation of deucrictibant as a preventive, or prophylactic, treatment for hereditary angioedema (HAE). Called CHAPTER-3, the trial will assess the treatment’s safety and efficacy…

One NTLA-2002 dose lowers rate of monthly HAE attacks by 98%

NTLA-2002, the investigational gene-editing therapy from Intellia Therapeutics, reduced the number of monthly swelling attacks by a mean of 98% among people with hereditary angioedema (HAE) who were treated in the Phase 1 portion of an ongoing Phase 1/2 clinical trial. The one-time treatment also led to sustained,…

Most HAE patients surveyed say they can predict swelling attacks

Most people with hereditary angioedema (HAE) can usually predict an impending swelling attack based on early, or prodromal, signs or symptoms, according to an online survey. However, results showed differing behaviors and definitions for “early treatment,” with 60% of the participants taking medications as soon as early symptoms…

Neck trauma serves as angioedema trigger in woman on telmisartan

An 83-year-old woman suddenly developed angioedema of the airway as a result of neck trauma while being treated with telmisartan, a medication commonly used to lower blood pressure, according to a case report from the U.S. “This case report highlights the rare and often forgotten adverse reaction of angioedema…